Staff editor
AcuraBio is a globally focussed organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries.
Metabolon and the Oxford Parkinson's Disease Centre will identify new metabolomic biomarkers to advance Parkinson's research and detect new therapeutic targets
Maria Teresa Abreu (University of Miami, USA) discussed some new strategies to design clinical trials.
Theresa Pizarro, (Case Western Reserve University School of Medicine) discussed the roles of epithelial barrier’s cytokines, gut microbiome and Gasdermin in IBD patients.
Sudarshen Paramsothy (University of New South Wales, Australia) discussed the controversials about FMT in IBD patients.
Herbert Tilg (University Innsbruck, Austria) discussed the relationship between Inflammatory Bowel Diseases and gut microbiome.
Niall Hyland (University College Cork) discussed the research on gut brain axis and the potential role of psychobiotics.
Simone Guglielmetti (University of Milan) discusses the use of inactivated microbes as alternative to live probiotics.
The partnership program aims to develop next-generation probiotics and therapeutics to modulate the gut microbiota to target areas like anxiety, depression and mental well-being.
It's the second agreement between Boehringer Ingelheim and BiomX focused on IBD. The first one in 2020.
